Pharmaceuticals - Political pressure

RECENT NEWS
The Times of India  Jan 25  Comment 
The arrest of ex-IDBI Bank chairman Yogesh Agarwal has shocked bankers, who see the move as a witch hunt against executives powerless to act in the face of political pressure and forced to extend loans to companies against their better business...
The Economic Times  Jan 24  Comment 
CBI's arrests on Monday shock bankers, who see the move as a witch hunt against their powerlessness to act in the face of political pressure.
Wall Street Journal  Jan 9  Comment 
Utilities are closing U.S. nuclear-power plants as they face competition from cheaper sources of electricity and political pressure from critics.
Wall Street Journal  Jan 8  Comment 
Fiat Chrysler’s move to invest $1 billion in U.S. plants comes as auto makers are facing heat from the incoming administration of President-elect Donald Trump to manufacture more vehicles in the U.S.
Reuters  Nov 16  Comment 
The election of Donald Trump as the next U.S. president could signal a period of heightened pressure on the Federal Reserve to change its accommodative stance, Barclays Chief Executive Jes Staley told a banking conference on Wednesday.
Wall Street Journal  Nov 9  Comment 
Donald Trump’s electoral victory could usher in a level of political pressure on the Federal Reserve not seen in decades.
MarketWatch  Nov 7  Comment 
Hillary Clinton backers are newly confident in her chances for victory; Newt Gingrich says FBI Director James Comey caved under political pressure; the election is shaping up to be the most wagered-upon political event ever; and more.
The Economist  Oct 30  Comment 
MARK Carney, the governor of the Bank of England, has upset many people in the Conservative party because of his warnings about the economic impact of Brexit. So some including former chancellor Lord Lawson and Daniel Hannan, a eurosceptic MEP,...
Forbes  Oct 12  Comment 
Diverse populations, political pressure, high financial risk – designing a pension system has its challenges and Peter A. Diamond considered all these obstacles in his analysis of welfare programs.




 
TOP CONTRIBUTORS

Prescription drug prices are often brought up in debates about the U.S. health care system as a whole. Many claim that pharmaceutical companies overcharge for their prescription drugs, making quality healthcare too expensive for some to afford. Drug companies cite the high costs of drug development as the reason for high end-user prices. They also often decry the length of patent protection, saying that they have to recoup all the money spent on development within a relatively limited period of time, forcing them to charge higher prices. Nonetheless, there is growing political pressure to lower prescription drug prices and relax the restrictions on generic drug production, despite pharmaceutical companies' warnings that this could slow or hinder the development of life-saving drugs.

An example of this political pressure is the recent bill passed by the House of Representatives aimed at lowering prescription drug costs for Medicare recipients. The bill repealed a previous provision that prevented the Secretary of Health and Human Services from negotiating with drug companies on behalf of Medicare recipients. Instead, the new bill requires that the Secretary conduct such price negotiations. This is aimed at lowering costs for Americans enrolled in Medicare prescription drug plans, though it would save the government money as well.

US Federal Reserve chairman Ben Bernanke warned of rising health costs and the effect it may have on the government budget. Lower income households would be the hardest hit because they depend the most on government help.[1]

Companies that benefit from increased regulation of pharmaceuticals

Health insurance companies

Companies hurt by increased regulation of pharmaceuticals

Pharmaceutical companies

The drug development process is costly and time-consuming, taking an average of $800 million and several years to develop just one commercially viable drug. Pharmaceutical companies cite these as reasons why they're forced to charge seemingly exorbitant prices for their products. If political pressure were to lead to increased regulation of drug prices or a relaxing of rules governing generics, large pharmaceutical companies would be negatively impacted.

Among the biggest issues facing the industry is the meaningful decline in the pace of new drug introductions combined with the pending patent expiration of some of the highest revenue producing drugs in the industry. Merck is likely to lose 25% of its revenue to patent expiration over the next 3 years, drugs like Vasotec, Prinivil, Pepsid, and Prilosec. Pfizer faces the patent expiration of Lipitor, it's $13 billion blockbuster, in 2011. Patented drugs are coming off patent faster than new drugs are being patented. This is steadily eroding the profitability of the industry as price per pill declines dramatically upon the introduction of generic competition, and operating margins move into the single digits. Firms are reacting with cuts in R&D and Sales Expenses, and are finding growth through acquisition and the economies of scale of size. The largest firms are moving toward a model that recognizes their core strength as distribution while innovation is purchased on the outside.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki